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Abstract
Purpose Interleukin (IL)-8 is a proinflammatory C-X-C chemokine involved in inflammation underling cardiac diseases, 
primary or in comorbid condition, such diabetic cardiomyopathy (DCM). The phosphodiesterase type 5 inhibitor sildenafil 
can ameliorate cardiac conditions by counteracting inflammation. The study aim is to evaluate the effect of sildenafil on serum 
IL-8 in DCM subjects vs. placebo, and on IL-8 release in human endothelial cells (Hfaec) and peripheral blood mononuclear 
cells (PBMC) under inflammatory stimuli.
Methods IL-8 was quantified: in sera of (30) DCM subjects before (baseline) and after sildenafil (100 mg/day, 3-months) 
vs. (16) placebo and (15) healthy subjects, by multiplatform array; in supernatants from inflammation-challenged cells after 
sildenafil (1 µM), by ELISA.
Results Baseline IL-8 was higher in DCM vs. healthy subjects (149.14 ± 46.89 vs. 16.17 ± 5.38 pg/ml, p < 0.01). Sildenafil, 
not placebo, significantly reduced serum IL-8 (23.7 ± 5.9 pg/ml, p < 0.05 vs. baseline). Receiver operating characteristic 
(ROC) curve for IL-8 was 0.945 (95% confidence interval of 0.772 to 1.0, p < 0.01), showing good capacity of discriminat-
ing the response in terms of drug-induced IL-8 decrease (sensitivity of 0.93, specificity of 0.90). Sildenafil significantly 
decreased IL-8 protein release by inflammation-induced Hfaec and PBMC and downregulated IL-8 mRNA in PBMC, without 
affecting cell number or PDE5 expression.
Conclusion Sildenafil might be suggested as potential novel pharmacological tool to control DCM progression through IL-8 
targeting at systemic and cellular level.
Keywords IL-8 · Sildenafil · Diabetes · Cardiomyopathy · Inflammation
Introduction
Low-grade inflammation is a critical component of chronic 
metabolic disorders such as type 2 diabetes (T2D) and is 
tightly associated with diabetes-induced vascular and car-
diac complications [1]. This general inflammatory status, 
recently referred to as ‘metaflammation’, is common to several S. Giannattasio, C. Corinaldesi and M. Colletti equally 
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comorbid conditions—cardiomyopathy, diabetes, athero-
sclerosis—and is usually characterized by T helper 1 (Th1) 
type immune dominance and related biomediators, such as 
cytokines and chemokines [2]. Several Th1 type biomolecules 
are engaged in inflammatory processes at systemic, cellular 
and biomolecular levels, i.e., interleukin (IL)-1, IL-6, IL-8, 
IL-10, IL-12, tumor necrosis factor (TNF)α, and interferon 
(IFN)γ. In particular, IL-8 is present since early stages of 
inflammatory response and remains active for long time [3]; 
remarkably, this chemokine seems widely involved in cardiac 
disease, either primary or secondary to dysmetabolism [4]. 
Indeed, IL-8 serum level is connected with atherosclerosis 
processes linked to cardiovascular events, in association with 
baseline cardiovascular risk [5]. Furthermore, higher circulat-
ing IL-8 level found in T2D patients vs. non-diabetic subjects 
was associated with worse inflammatory and cardiometabolic 
profile [6].
Nowadays, the class of drugs inhibiting phosphodiesterase 
type 5 (PDE5i), including sildenafil, vardenafil, tadalafil and 
avanafil, commonly used to treat erectile dysfunction (ED), 
is documented to exert blunting effects onto Th1-driven pro-
cesses and biomediators, likely through cGMP/cAMP stabi-
lization [7, 8]. In line with those observations, we have pre-
viously reported that sildenafil in diabetic cardiomyopathy 
(DCM) significantly decreased Th1 type chemokine CXCL10 
level, in blood and in human cardiomyocytes [9]. PDE5i seem, 
indeed, to elicit protective effects in several heart dysfunctions 
(either primary or secondary to other diseases) such heart fail-
ure, ischemia/reperfusion injuries, infarct, ventricular arrhyth-
mias, cardiopulmonary bypass [10–12].
In light of this evidence, it has been hypothesized that 
PDE5i-elicited cardioprotective effects may rely not only 
on their undeniable vasoactive action but also on their anti-
Th1 type inflammatory processes. Considering the pivotal 
role of IL-8 during inflammation-induced tissue/cell dam-
age in cardiac diseases, herein we aim to investigate whether 
sildenafil can target IL-8 level in T2D subjects with DCM 
and in human endothelial and peripheral immune cells under 
maximal Th1 inflammatory challenge. To this purpose, we 
measured IL-8 in sera from T2D patients at the onset of car-
diomyopathy secondary to diabetes, before and after chronic 
treatment with sildenafil (100 mg/day for 3 months) vs. pla-
cebo. Baseline chemokine levels were measured in sex- and 
age-matched healthy subjects. In addition, we investigated the 
effect of sildenafil onto IL-8 released by human endothelial 
and immune cells activated by IFNγ+TNFα or phytohaemag-
glutinin (PHA), respectively.
Materials and methods
Chemicals
Plastic for cell cultures and disposable filtration units were 
purchase from Corning (Milan, Italy). Dulbecco-modified 
eagle medium (DMEM)/Ham’s F-12 medium (ratio 1:1) 
with and without phenol red, RPMI-1640 Medium, phos-
phate-buffered saline  Ca2+/Mg2+-free (PBS), bovine serum 
albumin (BSA) fraction V, antibiotics, EDTA-trypsin solu-
tion, Bradford reagent were from Sigma-Aldrich Corp. (St. 
Louis, MO, USA). Fetal bovine serum (FBS) was from 
Hyclone (Logan, UT, USA). Recombinant human inter-
feron (IFN-γ) and recombinant human Tumor Necrosis 
Factor alpha (TNFα) were from  Peprotech® (RockyHill, 
NJ, USA). For RNA extraction, TRIzol RNA isolation rea-
gent was purchased by Ambion™; for reverse transcrip-
tion 10 mM dNTP mix, random primers, RNaseOUT™ 
Ribonuclease inhibitor and  SuperScript® III Reverse were 
purchased from Invitrogen.  SYBR® Green PCR Master 
Mix for qPCR was from Life Technologies™ (Applied 
 Biosystems®). All reagents for SDS-PAGE were from Mil-
lipore (Billerica, MA, USA). l-Glutamine was from Gibco 
Laboratories (Grand Island, NY). Polyclonal rabbit anti-
PDE5 and monoclonal mouse anti-β-actin were from Santa 
Cruz (CA, USA).
Subjects
Frozen samples from 46 subjects with DCM were ana-
lyzed (Clinical Trial Registration—URL: http://www.
clini caltr ials.gov. Unique identifier: NCT00692237) [13]. 
The protocol was approved by Hospital Ethics Committee 
Policlinico Umberto I—Sapienza University Hospital of 
Rome. This was a randomized controlled trial with patients 
allocated to receive 100 mg/day sildenafil for 3 months (30 
subjects) or placebo (16 subjects). Eligible men with T2D 
were recruited from the outpatient of Policlinico Umberto 
I—Sapienza University Hospital of Rome, the inclusion 
criteria were: T2D > 1 year; normal blood pressure (BP) 
or treated hypertension with achievement of a target 
of  ≤ 130/80 mmHg; glycated hemoglobin (HbA1c) < 10%; 
body mass index (BMI) < 40; Table 1 summarizes patient 
characteristics. The exclusion criteria were: prior or cur-
rent use of PDE5i; use of exogenous insulin, thiazolidine-
diones, or spironolactone; substance abuse; history of car-
diovascular disease, proliferative retinopathy, autonomic 
neuropathy; symptoms or signs of ischemic heart disease 
during cardiac evaluations at enrollment; contraindications 
to sildenafil use or cardiac magnetic resonance (CMR) 
imaging. Concomitant medications (anti-hypertensives, 
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statins, etc.) were not changed between the months prior 
to the study and 1 month after it has finished. All blood 
samples were collected from peripheral vein and serum 
was obtained by centrifugation (3000 rpm for 10 min at 
4 °C); aliquots were stored at −80 °C until analyzed.
One additional group of subjects, matched for sex and 
age, were analyzed for comparisons: 15 subjects without any 
pathology (healthy subjects). Written informed consent was 
collected for all subjects.
Cell cultures
Human fetal aortic endothelial cells (Hfaec) were obtained 
from aortic ascendant tracts collected after voluntary abor-
tion (10–12 weeks of gestation) characterized and main-
tained as described elsewhere [14]. Legal abortions were 
performed in authorized hospitals; certificates of consent 
were obtained. The use of human fetal tissue for research 
purposes conforms with the principles outlined in the Dec-
laration of Helsinki and was approved by the committee for 
investigation in humans of the Azienda Ospedaliero-Uni-
versitaria Careggi, Florence, Italy (protocol no. 6783–04).
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from buffy coats obtained from healthy adult anony-
mous donors in accordance with local ethical committee; 
approval by Azienda Policlinico Umberto I Rome Italy, 
accordance with the principles outlines in the Declaration 
of Helsinki; written consents were obtained. Heparinized 
blood, collected from peripheral vein, was centrifuged on 
Ficoll–Hystopaque gradient following manufacture’s proto-
col. PBMCs were cultured in RPMI supplemented with 10% 
FBS, 2 mmol/l l-glutamine and antibiotics.
IL‑8 secretion assays
Serum determination
Human serum levels of IL-8 were measured using a mag-
netic bead-based multiplex assay (Bio-Plex Pro™ Human 
Cytokine, Chemokine and Growth factor assay, Bio-Rad 
laboratories, Inc.) according to the manufacturer’s proto-
col. A broad sensitivity range of standards (between 1.95 
and 95.000 pg/ml; Bio-Rad Laboratories, Inc.) was used 
to enable the quantification of a dynamic wide range of 
cytokine concentrations and provide the greatest sensitiv-
ity. Data acquisition was performed by Bio-Plex 200 Sys-
tem™ (Bio-Rad Laboratories, Inc.) which uses Luminex 
fluorescent-bead-based technology (Luminex) with a 
flow-based dual laser detector with real-time digital signal 
processing to facilitate the analysis of up to 100 different 
families of color-coded polystyrene beads and allow mul-
tiple measurements of the sample ensuing in the effective 
quantification of cytokines. Data analysis was performed by 
Bio-Plex Manager™ 6.0 software (Bio-Rad Laboratories, 
Inc.). Serum samples were run in triplicate at least twice. 
Data were expressed as serum IL-8 concentration divided in 
“healthy” (subjects with no pathology), “baseline” (subjects 
with DCM before any therapy) and “+ sildenafil” and “+ 
placebo” (subjects with DCM and with sildenafil or placebo 
therapy after 3 months).
Cell supernatant determination
Hfaec (4000 cells/well) were seeded in 96-well flat bottom 
plates, maintained in phenol red- and serum-free medium 
overnight and incubated in serum-free medium containing 
0.1% BSA with sildenafil (1 µM) for 24–48 h; cells in serum-
free medium containing 0.1% BSA and vehicle were used 
as control.
PBMC (150,000 cells/well) were seeded in 96-well round 
bottom plates in their growth medium and stimulated with 
PHA (2%) with or without sildenafil (1 µM) for 24 h and 
48 h. Cells in growth medium with vehicle and PHA were 
used as controls. Sildenafil was added each day in each cell 
type.
Table 1  Clinical characteristics of the study populations
Values of the different clinical parameters did not differ between 
sildenafil and placebo arm
BMI body mass index, HOMAi Homeostasis model assessment index, 
HbA1c Hemoglobin A1c, HDL High-density lipoprotein, LDL Low-
density lipoprotein, BP Blood pressure, LVMi Left ventricular mass 
index, EDVi End-diastolic volume index, BNP brain natriuretic pep-
tide, NT proBNP N-terminal pro b-type natriuretic peptide
Variable Diabetic cardio-
myopathy sildenafil 
arm
Diabetic cardio-
myopathy placebo 
arm
Numbers 30 16
Age (years) 61.4 ± 1.4 60.7 ± 1.3
BMI (kg/m2) 28.4 ± 0.9 27.6 ± 0.8
Glycemia (mmol/L) 8.4 ± 1.9 8.2 ± 1.6
HOMA-index 6.3 ± 0.8 7.5 ± 0.8
HbAlc (%) 7.9 ± 0.2 7.3 ± 0.3
Total cholesterol (mmol/L) 4.8 ± 1.0 4.4 ± 0.2
HDL cholesterol (mmol/L) 1.05 ± 0.2 1.2 ± 0.06
LDL cholesterol (mmol/L) 3.01 ± 0.98 2.43 ± 0.20
Triglycerides (mmol/L) 1.4 ± 0.7 1.4 ± 1.1
Mean systolic BP (mm Hg) 136.1 ± 2.2 131.4 ± 2.8
Mean diastolic BP (mm 
Hg)
79.7 ± 1.6 78.9 ± 1.4
LVMi (g/m2) 124.6 ± 4.7 114.1 ± 5.9
EDVi (mL/m2) 61.4 ± 1.7 60.76 ± 2.3
Ejection Fraction (%) 61.6 ± 1.5 59.1 ± 1.90
BNP (pmol/L) 2.6 ± 0.3 3.02 ± 1.0
NT proBNP (pg/ml) 70 ± 11.9 72.2 ± 18.5
Serum IL-8 levels (pg/ml) 23.7 ± 6 130.33 ± 89.7
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IL-8 levels were measured in cell cultures supernatants 
using commercially ELISA (enzyme-linked immunosorbent 
assay) available kits, according to the manufacturer’s recom-
mendations (R&D Systems—Minneapolis). The sensitivity 
ranged was from 1.5 to 7.5 pg/ml for IL-8. The intra- and 
inter-assay coefficients of variation were 4.6 and 8.1%. Qual-
ity control pools of low, normal, and high concentrations for 
all parameters were included in each assay. Samples were 
assayed in triplicate or quadruplicate. Protein measure-
ment to normalize the concentration of secreted cytokines 
was performed as reported elsewhere [15]. Experiments 
were performed four times with different cell preparations. 
Data were expressed as percent of inhibition, calculated on 
IFNγ + TNFα- and/or PHA release, taken as 100%.
RNA extraction, reverse transcription and real‑time 
quantitative PCR
35,000 Hfaec were seeded in 35-mm culture dishes and 
maintained for 24 h in their growth medium; after 12 h star-
vation (medium without serum and without phenol red), 
cells were stimulated for 24 h with a combination of IFNγ 
(1000 U/ml) + TNFα (10 ng/ml) with or without sildena-
fil (1 μM), in serum-free medium with 0.1% BSA, cells in 
serum-free medium containing 0.1% BSA and vehicle were 
used as control; 200,000 PBMC were seeded onto 96-well 
round bottom plates in their growth medium and stimulated 
for 48 h with 2% PHA with or without sildenafil (1 μM), 
cells in growth medium and vehicle were used as control. 
Total RNA was extracted from cultured cells using  TRIzol® 
RNA Isolation Reagents (Ambion™) according to the manu-
facturer’s instructions and described also elsewhere [16]. 
Single-stranded cDNA was obtained by reverse transcrip-
tion of 1 μg of total RNA. RT-qPCRs were performed using 
7500 Real Time System (Applied  Biosystems®) with SYBR-
green fluorophore; 40 ng of cDNA were used as template 
and cycling parameters were 95 °C for 10 min, followed by 
40 cycles of 15 s at 95 °C, 1 min at 60 °C, 30 s at 95 °C, 
15 s at 60 °C. Fluorescence intensities were analyzed using 
the manufacturer’s software (7500 Software v2.05) and rela-
tive amounts were obtained using the 2 − ∆∆Ct method and 
normalized for the ß-actin. Data are expressed as percent 
of inhibition of IFNγ + TNFα- or PHA-induced IL-8 gene 
expression, taken as 100%. Primers for IL-8 were: forward 
(TCC TGA TTT CTG CAG CTC TGTG) and reverse (GTC 
CAG CAG AGC TCT CTT CCAT); for β-actin, forward (CTG 
AAC CCC AAG GCC AAC ) and reverse (AGC CTG GAT AGC 
AAC GTA CA).
Cell proliferation
For cell proliferation assay, Hfaec (4000 cells/well) and 
PBMC (150,000 cells/well) were seeded in 96-well flat and 
round bottom plates, respectively, as reported in cell super-
natant determination subparagraph.
In each cell type, sildenafil was added each day. Cell 
number counting was assayed by hemocytometer as previ-
ously reported [17].
Western blot analysis
Hfaec and PBMC were seeded and maintained for western 
blot analysis, until they reach sufficient number to lyse in 
RIPA Buffer. Protein concentration measurement was per-
formed with Bradford Reagent. Protein aliquots (20 μg) were 
processed, loaded in 10% SDS-PAGE gel, transferred on 
nitrocellulose membranes, and incubated with primary Abs 
appropriately diluted in Tween Tris-buffered saline (TTBS; 
for anti-PDE5 1:500), followed by peroxidase-conjugated 
secondary IgG (1:10,000). Proteins were revealed by the 
enhanced chemiluminescence system (ECL plus; Milli-
pore). Image acquisition was performed with Image Quant 
Las 4000 software (GE Healthcare). Western blot analysis 
was performed for three experiments with different cell 
preparations.
cGMP quantification
cGMP determination has been performed onto  106 cells after 
overnight starvation and 30 min incubation with or with-
out sildenafil, using a commercially available kit (cGMP 
ELISA Kit from Enzo Life Sciences; Vinci, Fi, Italy) with 
3-isobutyl-1-methylxanthine (IBMX) as internal positive 
assay control.
Statistical analysis
Our research was conceived as a “proof of concept” study. 
The statistical analysis was performed using 12.0 SPSS 
(SPSS Inc, Chicago, IL, USA). The Kolmogorov–Smirnov 
test was used to test for normal distribution of the data. 
Continuous data were compared using unpaired Student’s t 
test or Mann–Whitney test when request. Receiver operat-
ing characteristic (ROC) curve was constructed to assess 
the capacity of discriminating the response in terms of 
sildenafil-induced IL-8 decrease. Briefly, ROC curve gives 
a graphic representation of the relationship between true-
positive fraction (sensitivity) and false-positive fraction 
(1-specificity). ROC curve can be assessed by plotting the 
values of 1-Sp against Se in a squared box, where the ROC’s 
area under the curve (AUC) is used to measure the perfor-
mance of a diagnostic test. The AUC range is in the interval 
0.5–1.0, so that the greater the area, the better the perfor-
mance of the variable being examined. Sigmoid curves were 
performed using GraphPad Prism 5 software (GraphPad 
Software, Inc., La Jolla, CA, USA) and SPSS 12.0 software 
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package. A P value less than 0.05 was considered significant 
and corrected for comparison using the Dunnett’s or Bonfer-
roni’s post hoc test, where appropriate. Data were expressed 
as mean ± SE.
Results
IL‑8 levels in healthy subjects and DCM patients 
before and after sildenafil or placebo intake
To verify whether PDE5i could affect serum IL-8, we meas-
ured the chemokine blood level in DCM subjects before 
(baseline) and after sildenafil or placebo intake vs. healthy 
subjects.
In DCM patients, baseline IL-8 levels were about ten-
fold higher vs. healthy subjects (149.14 ± 46.89  pg/ml 
vs. 16.17 ± 5.38 pg/ml, p < 0.01) (Fig. 1). Sildenafil after 
3 months decreased IL-8 close to similar values as found 
in healthy subjects (23.7 ± 6 pg/ml, p < 0.05 vs. baseline), 
whereas placebo left essentially unvaried baseline IL-8 in 
blood (130.33 ± 89.74 pg/ml) of DCM patients.
Assessment of IL‑8 serum response to sildenafil 
in DCM patients
To further estimate the effect of sildenafil in DCM patients, 
we analyzed IL-8 serum level constructing ROC curve 
based on the response to sildenafil. Responders (r) and 
non-responders (nr) to sildenafil were defined as those 
patients who had positive or null/negative response to the 
drug, respectively. R and nr had IL-8 baseline value of 
197.55 ± 101.8 pg/ml and − 16.05 ± 6.97 pg/ml, respectively 
(Fig. 2a). Out of all clinical parameters analyzed, B-type 
natriuretic peptide (BNP), used as clinical biomarker for 
congestive heart failure diagnosis, was significantly higher 
in r vs. nr (p < 0.05, inset of Fig. 2a), albeit within normal 
range.
Fig. 1  Serum IL-8 levels in DCM patients before (baseline) and 
after 3  months sildenafil or placebo, vs. healthy subjects. DCM 
patients showed higher baseline levels of IL-8 vs. healthy subjects 
(149.14 ± 46.89 pg/ml vs. 16.17 ± 5.38 pg/ml); IL-8 was significantly 
reduced (23.7 ± 6  pg/ml) close to healthy levels in DCM patients 
after sildenafil. Conversely, serum IL-8 remained high after placebo 
(130.33 ± 89.74 pg/ml). *p < 0.05 vs. baseline; °°p < 0.01 vs. healthy. 
Results (mean ± SE) are expressed as serum IL-8 (pg/ml)
Fig. 2  Effect of sildenafil on circulating IL-8 in subjects with DCM. 
a IL-8 serum level categorized DCM patients as responders (r) and 
non-responders (nr) to sildenafil; positive 197.55 ± 101.8  pg/ml) or 
null/negative (− 16.05 ± 6.97  pg/ml) variation was observed after 
sildenafil intake; *p < 0.05  rvs. nr. Inset: Baseline BNP was sig-
nificantly higher in r vs. nr, *p < 0.05. Data of IL-8 (mean ± SE) 
are expressed as serum variation vs. baseline level (pg/ml); BNP 
(mean ± SE) was expressed as pmol/l. b. Receiver operating char-
acteristic (ROC) curve. The area under the ROC curve is 0.945 
(95% confidence interval of 0.772 to 1.0, p < 0.01), with a sensitivity 
of 0.93 and a specificity of 0.90
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Receiver operating characteristic (ROC) curve for 
IL-8 was 0.945 (95% confidence interval of 0.772 to 1.0, 
p < 0.01), showing good capacity of discriminating the 
response in terms of drug-induced IL-8 decrease (sensitivity 
of 0.93, specificity of 0.90) (Fig. 2b). ROC analysis identi-
fied a low IL-8 cut-off value (12.25 pg/ml).
Effect of sildenafil onto IL‑8 protein secretion 
and gene expression in Hfaec and PBMC
To verify whether PDE5 inhibition might affect Th1-driven 
IL-8 at cellular level, we investigated the effect of sildenafil 
(1 µM) onto chemokine protein secretion and gene expres-
sion in Hfaec and in PBMC after maximal inflammatory 
challenge (with IFNγ + TNFα or PHA, respectively) (Fig. 3). 
Drug concentration was chosen based on the near therapy 
dose, according to pharmacokinetics (Cmax and area under 
the time–concentration curve).
Sildenafil significantly inhibited IL-8 protein release by 
over 50% in Hfaec and 30% in PBMC (p < 0.01 and p < 0.001 
vs. inflammatory stimuli-induced secretion, taken as 100%). 
IL-8 mRNA expression was also significantly reduced by 
sildenafil in PBMC (p < 0.01 vs. PHA-induced IL-8 gene 
expression, taken as 1), whereas it was unaffected in Hfaec 
(inset of Fig. 3).
cGMP measurement and PDE5 expression 
before and after sildenafil in Hfaec and PBMC
Since sildenafil is a selective cGMP-dependent inhibitor 
of PDE5 activity, we measured cGMP amount and PDE5 
expression in human endothelial and immune cells before 
and after sildenafil (Fig. 4).
Sildenafil (1 µM) significantly increased cGMP level 
after 30 min in Hfaec (p < 0.05 vs. control; Fig. 4a); cGMP 
in PBMC showed the same trend to rise after sildenafil, 
although not reaching statistical significance, like due to the 
high number variability linked to data deriving from isolated 
PBMC (Fig. 4b). PDE5 protein expression neither changed 
in Hfaec (inset of Fig. 4a) nor in PBMC (inset of Fig. 4b) 
after exposure to sildenafil (1 µM) for 24 h.
Effect of sildenafil on Hfaec and PBMC cell number
To exclude that sildenafil could affect human endothelial or 
immune cell number, we performed proliferation tests and 
found no significant effect in Hfaec and PBMC after 24–48 h 
exposure to sildenafil (1 µM) as compared with control cells 
(Fig. 5a, b).
Discussion
The main finding of the study is that sildenafil, not placebo, 
significantly reduced the higher IL-8 serum concentra-
tion associated with DCM to similar levels as in healthy 
subjects. ROC curve for IL-8 showed good capacity to 
discriminate the response in terms of sildenafil-induced 
serum IL-8 decrease. Furthermore, sildenafil inhibited IL-8 
protein release by inflammation-activated human immune 
and endothelial cells, likely with transcriptional and post-
transcriptional regulation.
The research onto inflammatory diseases has rapidly pro-
gressed in the last 50 years leading researchers and physi-
cians to redefine many diseases as “inflammatory” disor-
ders, including metabolic and heart diseases [18, 19]. The 
concept of metaflammation as the first trigger common to 
several pathologies has come from growing evidence on 
the association between chronic inflammatory diseases 
and elevated blood levels of inflammatory markers [20, 
21]. Th1 type chemokines regulate several inflammatory 
mechanisms considered the signature of metaflammation, 
essentially orchestrating immune cell recruitment and com-
plex inter- and intracellular signaling. Among those bio-
mediators, IL-8 or CXCL8, a prototypical chemoattractant 
component of ELR + C-X-C chemokine subfamily, derives 
from a variety of tissue and blood cells, and it is responsible 
for and involved in a wide range of inflammatory processes 
determining vascular bed homeostasis unbalance, with 
Fig. 3  Effect of sildenafil on IL-8 release induced by inflammatory 
stimuli in Hfaec and PBMC. IL-8 protein release was significantly 
counteracted by sildenafil in Hfaec and PBMC (percent of inhibi-
tion 54.54% ± 1.09 and 32.80% ± 0.55); results (mean ± SE) are 
expressed as percent of inhibition, calculated on IFNγ + TNFα- or 
PHA-induced IL-8 maximal secretion, taken as 100%; ***p < 0.001, 
**p < 0.01. Inset: IL-8 mRNA expression was reduced only in PBMC 
treated with sildenafil. mRNA levels—relative to β-actin mRNA, 
used as endogenous control—are expressed as (mean ± SE) percent 
of inflammatory stimuli-induced IL-8 mRNA expression, taken as 1; 
**p < 0.01. Data are obtained from three to seven experiments in trip-
licate, using different cell preparations
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consequence on endothelial mediator release and vascular 
tone [22]. Remarkably, each cellular component in the vas-
cular wall has been identified as a potential source of IL-8 
significantly contributing to the inflammatory micro-envi-
ronment maintenance of the injured vascular bed [3]. Differ-
ently from many other proinflammatory molecules, typically 
made and cleared in vivo within hours, IL-8 is present early 
and remains active for a prolonged time [3] during inflam-
matory response. IL-8 retains distinct target specificity for 
neutrophils which, once recruited, release granule enzymes 
degrading connective tissue constituents and determining 
intra- and extracellular injurious re-arrangements [23]. 
Transendothelial cell migration in chronic setting induced by 
IL-8 underlies endothelial dysfunction, as reported in several 
vascular diseases, from atherosclerosis, to aortic aneurysm 
formation and hypertension [24].
Thus far, since endothelial instability underlies cardiac 
disease in the presence or absence of comorbidity [25, 26], 
the ability of sildenafil to counteract vascular inflammation 
by targeting IL-8 could potentially be of clinical interest. 
Previous data showed that daily administration of sildenafil 
reduced vascular inflammation and improved endothelial 
function in T2D patients [27]. Clinical evidence sustains 
a strong association between PDE5i use and reduced mor-
tality rate and hospitalization in a cohort of T2D patients 
with attendant high cardiovascular risk [28]. PDE5 inhi-
bition seems also to exert favorable effects by enhancing 
enzymatic antioxidant system capacity [29]. Of note, those 
Fig. 4  Effect of sildenafil on cGMP stabilization and PDE5 expres-
sion. a cGMP concentration was significantly higher in Hfaec treated 
with sildenafil (1 µM, 30 min); *p < 0.05 vs. control cells. Inset West-
ern blot analysis showed no changes of PDE5 protein expression in 
Hfaec before and after sildenafil; β-actin was used as loading control. 
b cGMP amount in PBMC after 30 min of sildenafil (1 µM) showed 
a trend to increase though not statistically different vs. control. Inset 
Western blot analysis showed no changes in PDE5 protein expres-
sion before and after sildenafil; β-actin was is the loading control. 
Results in panel A (mean ± SE) are expressed as cGMP concentration 
(pmol/106 cells) and derived from two different preparations for each 
cell type; the blots in panel a and b are representative of data deriving 
from two/three different preparations of both cell types
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effects were not achieved with other class of vasoactive 
drugs as prostaglandins.
Concerning IL-8 cut-off low level (12.25 pg/ml), we 
observed that it was below the mean IL-8 concentration 
found in healthy subjects. Thus, we only can speculate that 
DCM patients would get benefit from sildenafil in terms of 
chemokine decrease when their baseline IL-8 value is much 
higher than that cut-off level.
Of note, the majority of DCM subjects classified as r 
to sildenafil concerning serum IL-8 level was previously 
grouped as r to the drug in terms of serum CXCL10, a Th1 
type ERL chemokine [9], and also retained higher baseline 
BNP, although still within normal reference range.
We speculate that DCM subjects showing from the begin-
ning higher Th1-type inflammatory chemokines might be 
perhaps more prone to progress in cardiomyopathy.
Moreover, sildenafil significantly counteracted IL-8 pro-
tein release from endothelial and immune cells—both known 
sources of the chemokine contributing to amplify inflamma-
tion—likely through post-transcriptional mechanism(s) in 
Hfaec, and transcriptional regulation in PBMC.
While in Hfaec sildenafil effect is undeniably mediated by 
cGMP stabilization as reflected by the significant increase, 
cGMP rise in sildenafil-treated PBMC, albeit showing a 
trend to increase, did not reach statistical significance, likely 
due to high number variability. PDE5 protein expression was 
not modified by sildenafil in either cell type in line with 
the previous literature [30]. However, detectable increase in 
PDE5 protein expression is reported after longer times (up 
to 7-days incubation) and higher dosage (25 µM) [31, 32].
In conclusion, from the present and previous data, 
sildenafil is able to target high level of ERL +/ERL–C-X-
C chemokines, as IL-8 and CXCL10, both known to play 
pivotal roles in initiation and progression of micro-environ-
mental immune/inflammatory processes leading to self-det-
rimental perpetuating loops established between local and 
systemic areas [33–35].
We would like to point out the potential clinical impact 
of C-X-C chemokine targeting, since those biomolecules 
act as immune/inflammatory triggers starting from an 
early temporal frame, likely preceding clinical cardiac sign 
manifestation. Indeed, while sildenafil modified metabolic 
parameters such as Hemoglobin A1c, post-prandial glyce-
mia and lipidemic profile [36], it failed to modify standard 
markers of chronic cardiac decompensation, such as ejec-
tion fraction, mass and volume index or blood pressure. 
We speculate on this (lacking) effect considering that all 
DCM patients enrolled were at the initial stage of cardiac 
disease, with no clinical signs of ischemia and left ven-
tricular (LV) function well preserved.
Accordingly, it has been shown that T2D man with 
ED still asymptomatic for cardiovascular disease showed 
higher monocyte oxidative activity and endothelial dys-
function [37], both additionally reduced with sildenafil 
given in combination with l-carnitine [38].
Likely, medium/long term follow-up would reveal 
whether sildenafil-induced IL-8 inhibition in blood could 
possibly relate with variation of some clinical parameters 
associated with patient status.
In addition, further medium/long-term investigations 
likely will elucidate whether the lack of any modifica-
tion of circulating IL-8 after 4 weeks of sildenafil in T2D 
patients, as previously reported [39] could be possibly 
explained with differences in treatment, including time-
frame and protocols.
So far, our results support the hypothesis that sildenafil 
could be a good candidate as a therapeutic option (may be as 
sparing-agent?) in patients with metabolic disorders, includ-
ing comorbid conditions, at increased risk of cardiovascular 
Fig. 5  Effect of sildenafil on human cardiac, endothelial and immune 
cell viability. a Hfaec cell number did not change after sildenafil 
(1 µM) for 24 h or 48 h vs. control (without drug). b PBMC cell num-
ber was not modified by sildenafil (1 µM) after 24 h and 48 h vs. con-
trol cells. Results derived from at least four different cell preparations 
for each cell type and are expressed as (mean ± SE)
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abnormalities, often ameliorated by testosterone replacement 
[40, 41]. Furthermore, sildenafil retains a better cardiovascu-
lar profile vs. other PDE5i, as demonstrated by well-estab-
lished overall safety after its use, with the limitation to avoid 
co-administration with long- and short-acting nitrate prepa-
rations [42]. More recently, it has been reported in animals 
that PDE5 inhibition by sildenafil, not tadalafil, decreased 
edema in lung ischemia–reperfusion injury during cardio-
pulmonary blocks [43].
Our investigation has several limits besides the small 
sample size analyzed, first the lack of subjects affected by 
T2D or cardiomyopathy alone with and without sildenafil 
treatment. Moreover, considering the high number of bio-
mediators engaged in metaflammation during comorbid 
conditions, it is mandatory to analyze a combination/ratio 
of biomediators. As an example, when evaluating vascular 
homeostasis and inflammation in diabetes, it is mandatory to 
consider molecules such as angiopoietins, critically involved 
in those processes [44]. Indeed, integrated analysis including 
an amplified number of noninvasive biomarkers aimed to 
obtain implemented algorithms has been recognized since a 
while to retain better predictive values, useful for validated 
decision models in several diseases [45, 46]. Due to their 
positive impact on both patients health care and efficient use 
of resources, standard risk algorithms incorporating different 
type of biomarkers, i.e., including sex/gender-related vari-
ables, are nowadays strongly encouraged also in T2D and its 
complications [47–49]. In this direction, we are planning our 
future investigations. Finally, the observed cut-off value of 
IL-8 resulted very low and below the mean IL-8 concentra-
tion found in healthy subjects. Hence, we believe that our 
findings are to be mitigated and taken cautiously, as they 
need to be confirmed in larger sample size studies.
Nevertheless, previous and present data suggest that 
sildenafil could be recommended with the novel indica-
tion to control metabolic status and early stage inflamma-
tory processes underlying DCM and warrant further in vivo 
and in vitro studies on PDE5i-promoted cardioprotection 
to assess the related fine-tuned biomolecular mechanisms.
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